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Resistance to different classes of drugs is associated with impaired apoptosis
in childhood acute lymphoblastic leukemia
Amy Holleman, Monique L. den Boer, Karin M. Kazemier, Gritta E. Janka-Schaub, and Rob Pieters
Resistance of leukemic cells to chemo-
therapeutic agents is associated with an
unfavorable outcome in pediatric acute
lymphoblastic leukemia (ALL). To investi-
gate the underlying mechanisms of cellu-
lar drug resistance, the activation of vari-
ous apoptotic parameters in leukemic
cells from 50 children with ALL was stud-
ied after in vitro exposure with 4 impor-
tant drugs in ALL therapy (prednisolone,
vincristine, L-asparaginase, and daunoru-
bicin). Exposure to each drug resulted in
early induction of phosphatidylserine (PS)
externalization and mitochondrial trans-
membrane (m) depolarization followed
by caspase-3 activation and poly(ADP-
ribose) polymerase (PARP) inactivation in
the majority of patients. For all 4 drugs, a
significant inverse correlation was found
between cellular drug resistance and (1)
the percentage of cells with PS external-
ization (< .001 < P < .008) and (2) the per-
centage of cells with m depolarization
(.002 < P < .02). However, the percent-
age of cells with caspase-3 activation and
the percentage of cells with PARP inacti-
vation showed a significant inverse corre-
lation with cellular resistance for pred-
nisolone (P  .001; P  .001) and
L-asparaginase (P  .01; P  .001) only.
This suggests that caspase-3 activation
and PARP inactivation are not essential
for vincristine- and daunorubicin-induced
apoptosis. In conclusion, resistance to 4
unrelated drugs is associated with de-
fect(s) upstream or at the level of PS
externalization and m depolarization.
This leads to decreased activation of apop-
totic parameters in resistant cases of pediat-
ric ALL. (Blood. 2003;102:4541-4546)
© 2003 by The American Society of Hematology
Introduction
Although combination chemotherapy has improved the prognosis
of childhood acute lymphoblastic leukemia (ALL) over the last few
decades, relapse still occurs in 20% to 30% of the cases.1 Cellular
drug resistance measured at initial diagnosis is associated with an
increased relapse risk and unfavorable clinical outcome in child-
hood ALL.2,3 In addition, the presence of adverse clinical prognos-
tic factors such as older age ( 10 years) and pro-B and T-lineage
immunophenotype have been shown to be associated with cellular
resistance to drugs in children with ALL.4 These findings indicate
that cellular drug resistance (measured in vitro) can be used as a
tool to identify patients at higher risk of treatment failure.
Chemotherapeutic agents have been described to induce apopto-
sis in malignant cells.5 There are 2 major routes by which apoptosis
can be induced: the extrinsic or death receptor–associated route and
the intrinsic or mitochondrial route. Although there is disagreement
concerning the role of the extrinsic route in chemotherapy-induced
apoptosis,6,7 there is a general agreement regarding the importance
of the intrinsic route. The intrinsic route can be subdivided into 3
general phases:8 (1) insult generation, (2) signal transduction, and
(3) execution. During the insult generation phase, chemotherapeu-
tic agents interact with and cause damage to their specific cellular
targets. The signal transduction phase is the least-defined phase and
is thought to involve integration of pro- and antiapoptotic signals.
The relative abundances of pro- and antiapoptotic signals, that can
be influenced by anticancer drugs,9 ultimately determines if the
execution phase is initiated.10 The execution phase is initiated by
release of cytochrome c and other polypeptides from the mitochon-
drial intermembrane space.11 This release is accompanied by a
dissipation of mitochondrial inner transmembrane potential (m).12
Once released in the cytoplasm, cytochrome c interacts with Apaf-1
(apoptotic protease-activating factor-1), adenosine triphosphate–
deoxyadenosine triphosphate (ATP/dATP), and procaspase-9 to
form a complex known as the apoptosome.13 In the apoptosome,
caspase-9 is activated which in turn activates effector caspases, like
procaspase-3 and -7.14 The effector caspases cleave a number of
structural and regulatory cellular proteins (eg, poly(ADP-ribose)
polymerase [PARP], lamins) and are responsible for the typical
morphologic and biochemical features of an apoptotic cell.15,16 A
simplified overview of the events taking place during chemotherapy-
induced apoptosis is given in Figure 1.
The fact that a point of convergence in the cellular response to
cytotoxic drugs appears to be apoptosis and that leukemic cells
display cross-resistance to drugs with different mechanisms of
action has led to the hypothesis that cellular drug resistance may be
related to defects in the apoptotic route. Aberrations at various
levels of the apoptotic route have been linked to a drug-resistant
phenotype in cell lines: absence of cytochrome c release,17,18
defective Apaf-1 activity,19-21 and caspase deficiency.22-24 However,
the occurrence of apoptotic defects has not been studied in children
with ALL. Therefore, the aim of this study was to determine
whether cellular drug resistance is associated with defects in
drug-induced apoptosis in pediatric ALL. To this aim, leukemic
cells of 50 children with newly diagnosed ALL were exposed in
vitro to 4 structurally unrelated drugs used in induction therapy of
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ALL, and activation of various apoptotic parameters was evaluated
(Figure 1).
Materials and methods
Patient samples
Bone marrow (BM) and/or peripheral blood (PB) were obtained from
children with newly diagnosed ALL who entered the Sophia Children’s
Hospital or one of the hospitals participating in the German Cooperative
Acute Lymphoblastic Leukemia (COALL) study. Within 24 hours after
sampling, mononuclear cells were isolated by density gradient centrifuga-
tion with a Ficoll-Isopaque gradient (Lymphoprep 1.077 mg/mL; Nycomed
Pharma, Oslo, Norway). Cells were resuspended in culture medium
consisting of RPMI 1640 Dutch modification without L-glutamine (Gibco
BRL, Breda, The Netherlands) supplemented with 20% fetal calf serum
(FCS; Integro, Zaandam, The Netherlands), 2  103 mol/L L-glutamine,
900 mol/L gentamycin (Gibco BRL), 100 IU/mL penicillin, 100 g/mL
streptomycin, 0.125 g/mL fungizone (Gibco BRL), and 827 pmol/L
insulin, 5  103 g/L transferrin, and 2.89  105 mol/L sodium selenite
(ITS media supplement; Sigma Aldrich, Zwijndrecht, The Netherlands). If
necessary, the lymphoid cells were further purified to at least 90% leukemic
blasts by removing nonmalignant cells with immunomagnetic beads
(DynaBeads, Dynal, Oslo, Norway).
In vitro drug resistance assay
In vitro drug resistance for daunorubicin (DNR; Cerubidine, Rhoˆne-
Poulenc Rorer, Amstelveen, The Netherlands), vincristine (VCR; TEVA
Pharma, Mijdrecht, The Netherlands), L-asparaginase (ASP; Paronal,
Christiaens, Breda, The Netherlands), and prednisolone (PRED; Bufa
Pharmaceutical Products, Uitgeest, The Netherlands) was determined using
the 4-day MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbro-
mide) assay as described previously by Pieters et al.25 Briefly, round-
bottomed 96-well microculture plates were filled with 20 L of different
dilutions of a drug and stored at 20°C. Six concentrations of each drug
were tested in duplicate. The ranges of the final concentrations of these
drugs were as follows: DNR: 0.002 g/mL to 2.0 g/mL; VCR: 0.05
g/mL to 50 g/mL; ASP: 0.003 IU/mL to 10 IU/mL; and PRED: 0.008
g/mL to 250 g/mL.
Aliquots of 80 L cell suspension (2  106 cells/mL) were added to
each well. Four wells contained 100 L culture medium without drugs or
cells for blanking the plate reader and 8 wells contained 100 L culture
medium with cells and without drug for measuring control cell viability.
After incubating plates for 4 days at 37°C in a humidified incubator in 5%
CO2, 10 L MTT (5 mg/mL; Sigma) was added and the plates were
incubated for an additional 6 hours. During these 6 hours, the living cells
present in each well will reduce the yellow MTT tetrazolium salt to
purple–blue formazan crystals. The formazan crystals were dissolved with
100 L 0.04 N HCl-isopropanyl alcohol (acidified isopropanol). The
optical density (OD) of the wells, which is linearly related to cell number,26
was measured spectrophotometrically at 562 nm. Leukemic cell survival
(LCS) was calculated by the equation: LCS  (ODday4 treated well/mean
ODday4 control wells) 100%. The drug concentration lethal to 50% of the
ALL cells, the LC50 value, was used as a measure for cellular drug
resistance. MTT-assay results were only used if the drug-free control wells
contained at least 70% leukemic cells after 4 days of culture.
In vitro drug exposure for measuring apoptotic features
Fresh leukemic cells (2.0  106 cells/mL) with a purity of at least 90%
leukemic blasts were cultured in the presence of drugs at 37°C in a
humidified incubator in 5% CO2. The ranges of the final drug concentra-
tions were as follows: PRED: 0.061 g/mL to 250 g/mL; VCR: 0.195
g/mL to 50 g/mL; ASP: 0.016 IU/mL to 10 IU/mL; and DNR: 0.008
g/mL to 2.0 g/mL.
Measurement of aberrant phosphatidylserine externalization
on the outer cell membrane
During the early stages of apoptosis, phosphatidylserine (PS) is translocated
from the inner side of the plasma membrane to the outer leaflet of the cell
membrane. Annexin V is a Ca2-dependent phospholipid-binding protein
with high affinity for PS and can therefore be used to detect apoptotic cells.
Leukemic cells were resuspended in 200 LAnnexin V–Alexa 488 Reagent
(Nexins Research BV, Kattendijke, The Netherlands) and incubated for 15
minutes at 4°C. A total of 5000 events was analyzed by flow cytometry
(FACSCalibur, Becton Dickinson, Erembodegem, Belgium). Drug-induced
apoptosis was calculated according to the following formula: percentage of
apoptotic cells  100%  (D-C)/(100-C), where D represents the percent-
age of Annexin V–positive cells in the presence of a drug and C is the
percentage of Annexin V–positive cells in the absence of a drug (spontane-
ous apoptosis). The intra-assay coefficient of variation for measurements of
PS externalization was 3.4%.
Detection of apoptosis-associated alterations in m
Disruption of m was determined using 3,3	-dihexyloxacarbocyanine
iodide (DiOC6(3); Molecular Probes, Eugene, OR), a lipophilic cationic
dye that accumulates in the mitochondrial matrix driven by m.27 Loss of
m was visualized as a reduction in the signal in the FL1 channel.
Leukemic cells were incubated in 200 L phosphate-buffered saline (PBS)
containing 40 nM DiOC6(3) solution and incubated in a humidified
incubator for 30 minutes at 37°C in 5% CO2. A total of 5000 events was
analyzed by flow cytometry. Percentage of cells with decreased mitochon-
drial transmembrane depolarization (m2) was calculated with the
following formula: 100%  (D-C)/(100-C), where D represents the
percentage of cells with reduced DiOC6(3) accumulation in drug-treated
samples and C represents the percentage of cells with reduced DiOC6(3)
accumulation in untreated samples. The intra-assay coefficient of variation
for measurements of disruption of m was 4.5%.
Measurement of caspase-3 and PARP cleavage
Leukemic cells were fixed using 2% (vol/vol) 37% formaldehyde solution
in 100% acetone. Fixed cells were washed twice with PBS/0.1% bovine
serum albumin (BSA) and incubated with an antibody directed against
cleaved caspase-3 (Cell Signalling Technology, Beverly, MA) or cleaved
PARP (Cell Signalling Technology) at room temperature for 30 minutes.
Both antibodies recognize an epitope exposed only when both proteins are
cleaved during apoptosis. Subsequently, cells were washed and incubated
with fluorescein isothiocyanate (FITC)–conjugated rabbit antirabbit F(ab’)2
(DAKO, Glostrup, Denmark) for caspase-3 and FITC-conjugated pork
antimouse F(ab’)2 (DAKO) for PARP at room temperature for 30 minutes.
A total of 5000 events was measured by flow cytometry. Caspase-induced
PARP cleavage leads to PARP inactivation,15 hence we measured caspase-3
activation and PARP inactivation. The percentage of cells with caspase-3
activation or PARP inactivation was determined with the following
Figure 1. Simplified overview of the events taking place during drug-induced
activation of apoptotic parameters. Drugs A and B represent 2 structurally
unrelated drugs. Numbers 1, 2, and 3 refer to the 3 phases of the drug-induced
apoptotic route as described in “Introduction”: 1 indicates insult generation; 2, signal
transduction; and 3, execution. Parameters with an asterisk (*) are measured in this
study using flow cytometry; the right column indicates the detection method used.
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formula: 100%  (D-C)/(100-C), where D represents the percentage of
cells that stain positive for the antibody in drug-treated samples, and C is
the percentage of cells that stain positive for the antibody in untreated
samples. Intra-assay variation of caspase-3 and PARP cleavage measure-
ments was 11.2% and 11.8%, respectively.
Statistics
Correlations between different apoptotic parameters as well as between the
LC50 values and apoptotic parameters were calculated using the Spearman
rank (rs) correlation test. Statistical tests were performed at a 2-tailed
significance level of 0.05.
Results
Time-dependent induction of apoptotic parameters was studied in 5
children with ALL in order to determine the most suitable time
point for testing a larger group of children with ALL. In vitro
exposure to each of the 4 drugs tested caused a time-dependent
activation of apoptotic parameters in ALL cells as assessed by an
increase of cells with PS externalization, m depolarization,
caspase-3 activation, and PARP inactivation (Figure 2). In only one
patient were sufficient cells available to perform an extensive
concentration series. The data indicated a concentration-dependent
increase in the activity of all apoptotic parameters (data not shown).
Although exposure to all 4 drugs resulted in activation of
similar apoptotic parameters, a difference in apoptosis kinetics was
observed. Whereas daunorubicin and vincristine trigger a relatively
fast activation of apoptotic parameters, L-asparaginase and pred-
nisolone consistently induced apoptosis more slowly (Figure 2).
After 18 hours of daunorubicin or vincristine exposure the mean
percentage of cells with PS externalization in the 5 ALL samples is
52% 
 23% and 36% 
 21%, respectively. In contrast, the mean
percentage of cells with PS externalization after 18 hours of
L-asparaginase and prednisolone exposure was 20% 
 15% and
21% 
 31% compared with 30% 
 18% and 19% 
 19%, respec-
tively, after 42 hours. The 2 types of kinetics could be confirmed in
subsequent experiments; the mean percentage of cells with PS
externalization in the 50 patients measured in this study after 18
hours of daunorubicin or vincristine treatment are 60% 
 24% and
42% 
 25%, respectively, compared with 31% 
 19% and
30% 
 30% after 42 hours L-asparaginase and prednisolone expo-
sure, respectively. To be able to study the relationship between
apoptosis and cellular drug resistance in a large group of patients,
activation of apoptotic parameters was measured after 18 hours of
incubation with daunorubicin and vincristine and after 42 hours of
incubation with L-asparaginase and prednisolone in further experiments.
Figure 3 shows that the percentage of cells with PS externaliza-
tion is proportional to the percentage of cells with reduction in
mitochondrial transmembrane potential (rs  0.75, P  .001),
caspase-3 activation (rs  0.72, P  .001), and the percentage of
cells with PARP inactivation (rs  0.67, P  .001). Significant
correlations were also found when analyzing data from each of the
4 drugs separately (Table 1). The slopes of the regression lines in
Figure 3A-C are a  0.75, a  0.52, and a  0.44, respectively.
The closer the slope of the regression line approaches a  1.0, the
closer the event probably follows after PS externalization. This
indicates that upon drug exposure, PS externalization and m
depolarization are early events, whereas caspase-3 activation and
PARP inactivation are occurring relatively later.
Large interindividual variability in the extent of drug-induced
activation of apoptotic parameters was observed between patients.
For instance, prednisolone-induced PS externalization after 42
hours ranged between 26% and 86% (median: 27%). Figure 4
and Table 2 show for each individual drug highly significant
inverse correlations between the LC50 and (1) the percentage of
cells with PS externalization and (2) the percentage of cells with
m depolarization. However, caspase-3 activation and PARP
inactivation showed a less-consistent inverse correlation pattern
with cellular drug resistance. A significant inverse correlation
between cellular drug resistance and the percentage of cells with
caspase-3 activation was observed for prednisolone (rs  0.60,
P  .001) and L-asparaginase (rs  0.46, P  .01) but not for
Figure 2. Time-dependent drug-induced apoptosis in
ALL. Freshly isolated ALL cells were cultured in the pres-
ence of 2.0 g/mL daunorubicin (DNR;  ), 50 g/mL
vincristine (VCR; F), 10 IU/mL L-asparaginase (ASP; Œ),
or 250 g/mL prednisolone (PRED; ) for the indicated
time points. Drug-induced PS externalization (A), mito-
chondrial transmembrane disruption (B), caspase-3 acti-
vation (C), and PARP inactivation (D) were determined
by flow cytometry and calculated by the formula de-
scribed in “Materials and methods.” Results are ex-
pressed as mean
 SD of 5 patients with ALL.
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vincristine and daunorubicin. Likewise, PARP inactivation was
inversely correlated to cellular drug resistance for prednisolone
(rs  0.58, P  .001) and L-asparaginase (rs  0.58, P  .001)
only (Table 2).
Discussion
Cellular drug resistance may reflect disruptions in the apoptotic
route.17-24 Low caspase-3 activity has been previously linked to a
poor prognosis in adult chronic myelogenous leukemia (CML)28
and high levels of caspase-3 with improved survival in adult acute
myeloid leukemia (AML).29 In addition, loss of spontaneous
caspase-3 activation in vivo is associated with relapse in adults
with ALL.30 However, the presence and clinical significance of
these disruptions in the apoptotic route have not been studied well
in pediatric ALL. In the present study, we have analyzed drug-
induced activation of apoptotic parameters in leukemic cells taken
at initial diagnosis of ALL. PS externalization, m disruption,
caspase-3 activation, and PARP inactivation were measured after in
vitro exposure to 4 cytotoxic drugs that form the backbone of ALL
therapy: prednisolone, vincristine, L-asparaginase, and daunorubicin.
Time series experiments showed a fast activation of apoptotic
parameters for daunorubicin and vincristine and a slower activation
for L-asparaginase and prednisolone (Figure 2). One may speculate
that this reflects differences in primary cellular targets of the
different drugs. Hypothetically, a cell is likely to respond quickly to
the direct damaging effect of daunorubicin and vincristine treat-
ment, that is, DNA damage and microtubule damage, respectively.
In contrast, it may take a cell relatively longer to respond to the
indirect effects of L-asparaginase and prednisolone treatment, that
is, induction of gene expression or depletion of the intracellular
stock of the amino acid asparagine.
Our data suggest that PS externalization and disruption of m
are both early features of apoptosis induced by 4 structurally
unrelated drugs in childhood ALL (Figures 2-3). The spread of data
points around the line x  y in Figure 3 indicates that in half of the
patients, disruption of m appears to precede PS externalization
(dots above the line x  y). However, in the other half of the
patients, disruption of m follows or coincides with PS external-
ization. No consensus is reached in literature concerning the
sequence of these 2 apoptotic events. Conflicting reports have been
published showing that disruption of m either preceded or
coincided with or followed PS externalization.31-34 An explanation
for this phenomenon is proposed by Denecker et al,33 who suggest
that both m disruption and PS externalization are not necessarily
2 dependent but rather parallel events initiated after an apoptotic
stimulus. Consequently, the sequence of these 2 apoptotic events
may be cell type–, stimulus-, and apparently also patient-specific.
The present data show that resistance of leukemic cells to each
of 4 unrelated drugs is associated with decreased PS externalization
and m depolarization compared with sensitive cells. Caspase-3
activation or PARP inactivation was linked to cellular resistance to
prednisolone and L-asparaginase, but not with cellular resistance
toward vincristine and daunorubicin (Table 2). A possible explana-
tion for this observation is that caspase-3 and PARP cleavage may
be an epiphenomenon, which is not essential for vincristine- and
daunorubicin-induced apoptosis. Multiple caspases, which are
redundant in function, are expressed in acute leukemic cells.35
Possibly, in case of vincristine- and daunorubicin-induced apopto-
sis, a caspase other than caspase-3 may function as the main
effector caspase in primary ALL cells.
We found that cellular drug resistance is associated with
decreased PS externalization and m depolarization compared
with sensitive cells. Decreased activation of these apoptotic
parameters is likely to result from a defect upstream or at the level
of both PS externalization and disruption of m (Figure 5).
Aberrations in the expression of various molecules associated with
cellular drug resistance in mainly adult leukemia and cell lines have
been described in literature.36-49 Treatment with chemotherapeutic
drugs increases intracellular ceramide levels.36 Significantly re-
duced ceramide levels have been linked to drug resistance in adult
Figure 3. Correlation between drug-induced apopto-
tic parameters in pediatric ALL. Correlation between
the percentage of cells with PS externalization and m
depolarization (A), activated caspase-3 (B), or inacti-
vated PARP (C) in leukemic cells in vitro incubated with
prednisolone, vincristine, L-asparaginase, or daunorubi-
cin in 50 children with ALL. The dashed line represent the
line x  y and the solid line represents the linear regres-
sion line.
Table 1. Correlation between PS externalization and the downstream
apoptotic parameters upon drug exposure in pediatric ALL
Drug
m
depolarization
Caspase-3
activation
PARP
inactivation
Prednisolone
Correlation coefficient .81 .76 .76
P  .001  .001  .001
N 31 29 29
Vincristine
Correlation coefficient .80 .56 .64
P  .001  .001  .001
N 30 32 32
L-asparaginase
Correlation coefficient .42 .49 .56
P .017 .006 .002
N 32 30 29
Daunorubicin
Correlation coefficient .63 .50 .41
P  .001 .005 .029
N 29 31 29
Freshly isolated ALL cells were cultured for 18 hours in the presence of 50 g/mL
vincristine or 2.0 g/mL daunorubicin or 42 hours in the presence of 250 g/mL
prednisolone or 10 IU/mL L-asparaginase. Drug-induced activation of apoptotic
parameters was determined by flow cytometry. Correlation between apoptotic
parameters was calculated using the Spearman rank correlation test.
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patients with ALL, CML, and AML.37 Deficient up-regulation of
CD95 ligand and down-regulation of CD95 receptor expression has
been shown to confer drug resistance in leukemic cell lines.6,38
Aberrant expression of both anti- and proapoptotic Bcl-2 family
members is known to prevent mitochondrial permeability transition
pore opening and release of apoptogenic proteins from mitochon-
dria.39 Data regarding the role of the expression levels of Bcl-2
family members and clinical outcome in ALL are contradictory.40-43
Overexpression of the p53 regulator MDM2 has been associated
with early relapse, adriamycin resistance, and failure to respond to
reinduction therapy in childhood leukemia.44 In addition, constitu-
tive activation of antiapoptotic proteins such as both Akt/PKB45
and c-Raf46 as well as inactivation of the proapoptotic protein
PTEN47 have been linked to drug resistance in various types of
cancers. Other proteins whose overexpression is associated with
resistance to apoptosis in acute leukemia are members of the heat
shock protein family, including Hsp2748 and Hsp70.49 To find out
(1) which molecules play an actual role in cellular drug resistance
in children with ALL and (2) whether resistance to different drugs
is associated with drug-specific defects, we currently perform gene
expression studies using high-density oligonucleotide microarrays.
In conclusion, the present study shows that decreased PS
externalization and m depolarization are found in children with
ALL who are in vitro–resistant to structurally unrelated drugs.
These data suggest that cellular resistance to these drugs is caused
by defects upstream or at the level of mitochondrial function.
Figure 4. Drug-induced apoptosis inversely corre-
lates with cellular drug resistance in pediatric ALL.
Freshly isolated ALL cells were incubated in the presence
of vincristine (B) or daunorubicin (D) for 18 hours or
prednisolone (A) or L-asparaginase (C) for 42 hours at
37°C in a humidified incubator in 5% CO2. See Figure 2
for drug concentrations used. Each dot corresponds to a
patient with ALL.
Table 2. Inverse correlation between cellular drug resistance and
the activation of parameters along the effector route of apoptosis
in pediatric ALL
Apoptotic
parameter
LC50
prednisolone
LC50
vincristine
LC50
L-asparaginase
LC50
daunorubicin
PS externalization
Correlation
coefficient .59 .52 .72 .46
P  .001 .002  .001 .008
N 32 33 32 32
m depolari-
zation
Correlation
coefficient .43 .45 .45 .54
P .016 .014 .010 .002
N 31 30 32 29
Caspase-3
activation
Correlation
coefficient .60 .28 .46 .27
P .001 .118 .011 .146
N 29 32 30 31
PARP inacti-
vation
Correlation
coefficient .58 .34 .58 .27
P .001 .059 .001 .160
N 29 32 29 29
See legend of Table 1.
Figure 5. Impaired apoptosis in resistant compared with sensitive ALL cells. A
defect localized upstream of the mitochondria may lead to decreased activation of
downstream apoptotic parameters in resistant patients with ALL. Potential sites of defects
are indicated with a cross. Decreased activation of apoptotic parameters is illustrated
by the decreased size of the arrows in resistant compared with sensitive patients.
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Caspase-3 activation and PARP inactivation are suggested to play a
role in prednisolone- and L-asparaginase–induced apoptosis, but are not
essential to vincristine- and daunorubicin-induced apoptosis. The
nature of the defects upstream or at the level of PS externalization
and m depolarization in resistant cells of children with ALL are
not elucidated and will be the subjects of further research.
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